Avadel Pharmaceuticals-adr (AVDL) Technical Analysis
$10.23▲0.89%
Market is closed - opens 8 PM, 26 Dec 2024
Insights
- Avadel Pharmaceuticals-adr is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Avadel Pharmaceuticals-adr stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Avadel Pharmaceuticals-adr stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Avadel Pharmaceuticals-adr stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 41.21 | Neutral |
Stochastic | 34.29, 35.49 | Neutral |
Ultimate Oscillator | 45.54 | Neutral |
Stochastic Relative Strength Index | 61.33, 58.43 | Neutral |
Moving Average Convergence Divergence | -0.49, -0.58 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.41 | Sell |
20 | 10.45 | Sell |
50 | 12.12 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.35 | Sell |
20 | 10.66 | Sell |
50 | 11.71 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.48 | Neutral |
20 | 10.44 | Neutral |
50 | 12.33 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.17 | Buy |
20 | 9.94 | Sell |
50 | 10.24 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.27 | Buy |
20 | 10.04 | Buy |
50 | 9.85 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 10.88 |
Resistance L2 | 10.67 |
Resistance L1 | 10.4 |
Pivot Point | 10.19 |
Support L1 | 9.92 |
Support L2 | 9.71 |
Support L3 | 9.44 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.